Trilaciclib
- Generic Name
- Trilaciclib
- Brand Names
- Cosela
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30N8O
- CAS Number
- 1374743-00-6
- Unique Ingredient Identifier
- U6072DO9XG
- Background
Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer. CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis...
- Indication
Trilaciclib is indicated to reduce the incidence of chemotherapy induced myelosuppression in patients prior to receiving platinum and etoposide-containing or topotecan-containing chemotherapy regimens for extensive-stage small cell lung cancer.
- Associated Conditions
- Bone Marrow Suppression caused by Chemotherapy
- Associated Therapies
- -
Study of Trilaciclib and Lurbinectidin
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05578326
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05112536
- Locations
- 🇺🇸
UCLA Department of Medicine - Hematology/Oncology, Santa Monica, California, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05113966
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05071703
- Locations
- 🇨🇳
Hainan General Hospital, Haikou, Hainan, China
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT04887831
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Beacon Cancer Center PLLC, Coeur d'Alene, Idaho, United States
🇫🇷Institut Bergonié - Oncologie Médicale et Pédiatrique, Bordeaux cedex, Gironde, France
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
- Conditions
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04863248
- Locations
- 🇺🇸
Regional Cancer Car Associates, LLC, Little Silver, New Jersey, United States
🇺🇸Summit Medical Group, Florham Park, New Jersey, United States
🇺🇸Ironwood Cancer & Research Centers, Phoenix, Arizona, United States
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT04799249
- Locations
- 🇺🇸
Banner M.D. Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Florida Cancer Specialists - North (SCRI), Saint Petersburg, Florida, United States
🇺🇸Maryland Oncology Hematology, P.A., Clinton, Maryland, United States
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 326
- Registration Number
- NCT04607668
- Locations
- 🇺🇸
AZ Oncology Associates - HOPE, Tucson, Arizona, United States
🇺🇸Keck Medical Center of USC Pasadena, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- G1 Therapeutics, Inc.
- Registration Number
- NCT04504513
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
- Conditions
- Interventions
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT03041311
- Locations
- 🇺🇸
Loma Linda University, Loma Linda, California, United States
🇺🇸Northside Hospital - Georgia Cancer Specialists, Atlanta, Georgia, United States
🇺🇦Lviv State Regional Treatment and Diagnostics Oncology Center, Lviv, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.